Streetbeat News

CARM

Carisma Therapeutics, Inc.

Industry

Biotechnology

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Carisma Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 4:59 pm

Carisma Therapeutics announced that its cash and equivalents are expected to be sufficient to sustain its planned operations into the third quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:05 pm

CARISMA Therapeutics (NASDAQ:CARM) reported Q2 2024 GAAP EPS of $(0.27), beating the estimate of $(0.32). Sales were $9.197M, significantly surpassing the $3.925M estimate. This represents a 44.9% improvement in EPS and a 158.34% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:04 pm

Carisma Therapeutics has terminated its Manufacturing and Supply Agreement with Novartis Pharmaceuticals for its product candidate CT-0508, effective July 31, 2024. The company will focus on its follow-on product candidate CT-0525 and will incur a $4 million termination fee.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 8:47 pm

Carisma Therapeutics Inc. (NASDAQ:CARM) shares surged on Friday following a significant development in its collaboration with Moderna. Carisma nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for treating solid tumors, triggering a $2 million payment from Moderna. HC Wainwright & Co. reiterated a Buy rating with a price target of $8.

Portfolio Pulse from Vaishali Prayag

June 28, 2024 | 5:59 pm

Market-Moving News for June 28th includes significant movements for Protagonist Therapeutics, Trump Media & Technology Group, and Carisma Therapeutics. Protagonist Therapeutics will join the S&P SmallCap 600, Trump Media & Technology Group shares rose following a presidential debate, and Carisma Therapeutics shares surged after announcing a new development candidate in collaboration with Moderna.

Portfolio Pulse from ryanfaloona@benzinga.com

June 28, 2024 | 12:37 pm

HC Wainwright & Co. has reiterated its Buy rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 11:23 am

Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 11:00 am

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:35 pm

Carisma Therapeutics Inc. (NASDAQ:CARM) and Moderna, Inc. (NASDAQ:MRNA) have announced the nomination of their first in vivo CAR-M development candidate targeting Glypican-3 for the treatment of solid tumors, including hepatocellular carcinoma. This nomination triggers a $2 million milestone payment to Carisma.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 8:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.